top of page

Choosing the Right Platform for ADA Assays in Immunogenicity Studies: A Critical Decision

Updated: Apr 30

In the realm of biopharmaceutical development, understanding and mitigating the immunogenicity of therapeutic proteins is paramount. Antibody drug assays (ADA assays) serve as vital tools in assessing immunogenicity by detecting anti-drug antibodies (ADAs) in patient samples. However, selecting the appropriate platform for ADA assays is a critical decision that significantly impacts assay sensitivity, specificity, and reliability. This article explores the various platforms available for ADA assays and offers insights into choosing the right platform to support immunogenicity studies effectively.


Understanding ADA Assay Platforms: ADA assays can be performed using diverse platforms, each with its advantages and limitations. Common platforms include enzyme-linked immunosorbent assays (ELISA), electrochemiluminescence (ECL), radioimmunoassays (RIA), surface plasmon resonance (SPR), multiplex assays, and Gyrolab.

1. ELISA: ELISA is a widely used platform for ADA assays due to its simplicity, sensitivity, and scalability. ELISA involves the immobilization of drug molecules on a solid phase, followed by the detection of ADA-drug complexes using enzyme-conjugated detection antibodies. ELISA offers high throughput and compatibility with diverse sample matrices but may suffer from interference and matrix effects.

2. ECL: ECL assays utilize electrochemiluminescent detection methods, offering enhanced sensitivity and a broader dynamic range compared to traditional ELISA. ECL assays enable multiplexing and automation, making them suitable for high-throughput screening in immunogenicity studies. However, ECL platforms may require specialized equipment and expertise.

3. RIA: RIA relies on the competitive binding of radiolabeled and unlabeled antigens to detect ADAs in patient samples. While RIA provides exceptional sensitivity, it involves the use of radioactive isotopes, which raises safety and regulatory concerns. RIA is less commonly used in modern ADA assays due to the availability of alternative non-radioactive platforms.

4. SPR: SPR technology measures changes in refractive index as ADA-drug interactions occur on a sensor surface, offering real-time kinetics and label-free detection. SPR assays provide valuable insights into antibody binding affinity and epitope specificity but may require specialized instrumentation and expertise.

5. Multiplex Assays: Multiplex assays allow simultaneous detection of multiple analytes, including ADAs and drug concentrations, in a single sample. Multiplexing enhances efficiency and conserves sample volume, making it ideal for comprehensive immunogenicity assessments. However, multiplex assays may suffer from cross-reactivity and assay interference.

6. Gyrolab: Gyrolab is a microfluidic immunoassay platform that offers rapid and automated analysis of ADAs and other analytes. Gyrolab assays utilize nanoliter-scale volumes and parallel processing, enabling high sensitivity, precision, and throughput. Gyrolab's compact instrumentation and workflow automation streamline assay development and sample analysis, making it well-suited for immunogenicity studies.


Choosing the Right Platform: When selecting a platform for ADA assays in immunogenicity studies, several factors should be considered:

1. Sensitivity: Choose a platform with sufficient sensitivity to detect low levels of ADAs in patient samples, particularly in the presence of high drug concentrations. Platforms offering enhanced sensitivity, such as ECL, SPR, and Gyrolab, may be preferred for detecting low-affinity ADAs.

2. Specificity: Ensure that the chosen platform offers high specificity to distinguish between specific ADAs and nonspecific background signals. Evaluate assay specificity through rigorous validation studies using control samples and cross-reactivity assessments.

3. Throughput and Automation: Consider the throughput and automation capabilities of the platform to accommodate the scale and complexity of immunogenicity studies. Platforms offering high throughput and automation, such as ECL, multiplex assays, and Gyrolab, streamline sample processing and data analysis.

4. Sample Compatibility: Assess the compatibility of the platform with diverse sample matrices, including serum, plasma, and other biological fluids. Platforms with robust sample pre-treatment methods and minimal matrix effects, such as ELISA, ECL, and Gyrolab, are preferred for immunogenicity studies.

5. Regulatory Considerations: Consider regulatory requirements and guidelines governing ADA assay validation, standardization, and documentation. Choose a platform with established regulatory acceptance and a track record of compliance with industry standards.


The choice of platform for ADA assays in immunogenicity studies is a critical decision that significantly impacts assay performance, data quality, and regulatory compliance. By considering factors such as sensitivity, specificity, throughput, sample compatibility, and regulatory considerations, researchers can select the most suitable platform to support comprehensive immunogenicity assessments effectively. Whether utilizing established platforms like ELISA and ECL or innovative technologies like SPR, multiplex assays, and Gyrolab, the ultimate goal remains the same: to ensure the safety, efficacy, and quality of biotherapeutics for patients.


At Fleet Bioprocessing, we have the experience with a wide variety of platforms and can advise on how best to accomplish your study goals. We can support your assay from initial development through to ongoing supply of critical reagents, ensuring a robust and reproducible assay throughout your study. Contact us to see how we can help your study.


Recent Posts

See All

Scope Creep from IVDR into Regulated Bioanalysis

As industries evolve, so do regulations governing them. The In Vitro Diagnostic Regulation (IVDR) was introduced to enhance the safety and efficacy of in vitro diagnostic medical devices (IVDs) within

Comments


bottom of page